background
viral
respiratori
tract
infect
lead
caus
acut
ill
infanc
close
link
chronic
inflammatori
airway
diseas
later
life
howev
determin
suscept
acut
respiratori
tract
infect
still
need
defin
object
investig
whether
individu
variat
antivir
respons
birth
determin
risk
acut
respiratori
tract
ill
first
year
life
method
studi
children
enrol
birth
cohort
studi
innerc
children
least
parent
allergi
asthma
cultur
cord
blood
monocyt
assess
ifng
mrna
product
hour
inocul
respiratori
syncyti
viru
also
monitor
frequenc
acut
respiratori
tract
ill
interv
analyz
nasal
lavag
sampl
respiratori
tract
virus
time
ill
first
year
result
respiratori
tract
infect
report
subject
respiratori
tract
virus
recov
symptomat
children
observ
wide
rang
antivir
respons
cord
blood
monocyt
across
popul
furthermor
decreas
product
ifng
mrna
respons
respiratori
syncyti
viru
infect
monocyt
associ
signific
increas
frequenc
upper
respiratori
tract
infect
r
p
preval
ear
sinu
infect
pneumonia
respiratoryrel
hospit
conclus
individu
variat
innat
immun
respons
respiratori
tract
virus
detect
even
birth
differ
predict
suscept
acut
respiratori
tract
ill
first
year
life
j
allergi
clin
immunol
viral
respiratori
tract
infect
common
caus
earli
childhood
ill
infect
shortliv
selflimit
sever
enough
requir
hospit
inde
viral
respiratori
tract
infect
associ
mortal
children
less
year
age
addit
morbid
acut
infect
viral
respiratori
tract
infect
wheez
strong
indic
subsequ
asthma
therefor
predict
infant
risk
respiratori
tract
infect
import
first
step
prevent
acut
chronic
respiratori
diseas
previou
studi
identifi
varieti
potenti
risk
factor
viral
lower
respiratori
tract
infect
first
year
life
factor
includ
day
care
attend
number
sibl
small
lung
size
exposur
tobacco
smoke
low
birth
weight
prematur
birth
infect
caus
respiratori
syncyti
viru
rsv
particularli
implic
acut
ill
chronic
lung
diseas
first
year
life
howev
major
rsv
infect
infant
occur
without
known
risk
factor
thu
still
understand
precis
mechan
wide
variat
suscept
sever
respiratori
tract
infect
among
children
set
one
possibl
explan
rang
suscept
viral
respiratori
tract
infect
earli
childhood
defin
variat
antivir
respons
congenit
defici
innat
immun
respons
detect
even
time
birth
central
ingredi
innat
immun
respons
respiratori
virus
system
interferon
product
signal
regard
decreas
ifng
product
cord
blood
mononuclear
cell
cbmc
stimul
pha
allergen
associ
increas
risk
acut
respiratori
tract
ill
infanc
perhap
relev
viral
infect
lack
detect
ifng
respons
rsv
cbmc
associ
decreas
wheez
first
year
life
detect
respons
found
third
subject
therefor
predict
power
limit
therefor
present
studi
develop
altern
method
determin
whether
innat
immun
respons
virusinfect
cbmc
could
predict
later
develop
respiratori
tract
ill
use
rsv
activ
cbmc
base
wellestablish
associ
rsv
infect
subsequ
childhood
asthma
howev
monitor
innat
immun
respons
rsv
determin
induct
gene
encod
ifng
remark
virusrespons
chemokin
base
sensit
quantit
method
mrna
also
monitor
interferon
signal
transduct
track
level
signal
transduc
activ
transcript
stat
activ
respons
ifnb
stimul
case
use
culturedadher
cbmc
select
monocyt
versu
mix
cell
popul
includ
cell
previou
studi
assess
whether
immun
end
point
could
predict
develop
respiratori
tract
ill
first
year
life
prospect
birth
cohort
children
high
risk
asthma
allerg
diseas
experiment
matrix
led
unexpect
find
rsvinduc
ifng
gene
express
monocyt
predictor
subsequ
viral
respiratori
tract
ill
analyz
cord
blood
sampl
newborn
enrol
urban
environ
childhood
asthma
ureca
studi
group
repres
subset
children
enrol
st
loui
site
turn
subset
total
number
children
enrol
baltimor
boston
new
york
citi
site
februari
march
describ
previous
subject
requir
least
parent
allerg
rhiniti
eczema
andor
asthma
resid
area
greater
resid
poverti
level
well
born
week
gestat
later
st
loui
site
small
number
children
without
allerg
parent
n
also
recruit
comparison
enrol
subject
monitor
episod
acut
respiratori
tract
ill
next
year
along
quarterli
assess
respiratori
nonrespiratori
tract
ill
wheez
questionnair
nasal
lavag
sampl
obtain
caregiv
report
acut
respiratori
tract
ill
time
followup
visit
washington
univers
human
research
protect
offic
approv
studi
protocol
cord
blood
sampl
collect
deliveri
room
cbmc
isol
mean
densiti
gradient
centrifug
accuspin
tube
sigma
st
loui
mo
within
hour
collect
describ
previous
suffici
amount
sampl
avail
ie
subject
cell
resuspend
rpmi
medium
fb
mmoll
lglutamin
mmoll
nonessenti
amino
acid
final
concentr
per
millilit
plate
labtek
chamber
ml
per
well
nunc
roskild
denmark
realtim
pcr
assay
labtek
chamber
ml
per
well
activ
assay
describ
nonadher
cell
remov
hour
adher
cell
cultur
day
media
chang
day
remov
addit
nonadher
cell
end
cellcultur
period
adher
cell
greater
posit
immunostain
marker
monocyt
lineag
therefor
design
cord
blood
monocyt
cultur
approach
avoid
purif
method
eg
magnet
bead
select
fluorescenceactiv
cell
sort
modifi
cell
membran
cellcultur
method
eg
growth
factor
supplement
promot
full
differenti
polar
therebi
aim
obtain
cell
monocyt
lineag
repres
naiv
lung
tissu
monocyt
macrophag
target
viral
respiratori
tract
infect
vivo
cultur
day
cord
blood
monocyt
infect
rsv
strain
multipl
infect
equival
amount
uvinactiv
respiratori
syncyti
viru
rsvuv
cellular
rna
isol
immedi
hour
inocul
rnaeasi
mini
kit
qiagen
valencia
calif
transcrib
cdna
use
highcapac
cdna
revers
transcript
kit
appli
biosystem
foster
citi
calif
singletarget
quantit
realtim
pcr
use
monitor
ifng
mrna
rsv
rna
level
ifng
mrna
primer
obtain
appli
biosystem
rsv
rna
primer
probe
target
viral
l
gene
base
sequenc
rsv
strain
genbank
access
dehydrogenas
gapdh
mrna
primer
probe
use
plasmid
encod
ifng
origen
rockvil
md
portion
rsv
l
gene
nt
gapdh
gene
sequenc
genbank
access
use
gener
rna
standard
rtpcr
perform
use
taqman
realtim
pcr
master
mix
ml
sampl
cdna
accord
manufactur
protocol
appli
biosystem
data
gene
copi
number
normal
gapdh
level
subset
cord
blood
sampl
n
adequ
number
cell
also
assess
interferon
signal
transduct
monitor
level
phosphoryl
respons
interferon
stimul
correspond
cbmc
process
describ
serum
starv
day
cultur
cultur
day
cell
incub
ifnb
uml
minut
cell
lysat
harvest
treatment
cell
lysi
buffer
cell
signal
danver
mass
level
total
determin
use
elisa
invitrogen
carlsbad
calif
phosphoryl
level
determin
use
sandwich
elisa
pathscan
cell
signal
nasal
lavag
sampl
obtain
acut
respiratori
tract
ill
first
year
life
followup
visit
ill
sampl
respiratori
symptom
scorecard
complet
describ
previous
score
indic
moderatetosever
respiratori
tract
ill
site
staff
obtain
nasal
lavag
sampl
within
hour
nasal
lavag
sampl
process
identif
respiratori
tract
virus
use
pcrbase
assay
describ
previous
descript
data
express
percentag
mean
sd
median
interquartil
rang
nonnorm
distribut
data
test
differ
specif
group
x
fisher
exact
test
use
compar
categor
variabl
wherea
unpair
test
use
compar
continu
variabl
appropri
log
transform
made
data
yield
approxim
normal
distribut
nonnorm
distribut
data
wilcoxon
rank
sum
test
mannwhitney
u
test
use
compar
group
measur
standard
ratio
control
minim
variabl
daytoday
experi
follow
ifng
mrna
respons
rsv
ifng
mrna
copi
rsv
ifng
mrna
copi
without
rsv
mrna
respons
rsv
mrna
copi
rsv
mrna
copi
rsv
infect
rsv
level
express
rsv
rna
copi
number
infect
minu
valu
infect
spearman
correl
calcul
test
associ
variabl
examin
possibl
confound
follow
variabl
sex
breastfeed
matern
smoke
pregnanc
first
year
child
life
overal
sum
bedroom
allergen
exposur
mu
musculu
blattella
germanica
feli
domesticu
exposur
endotoxin
recombin
factor
c
assay
ergosterol
evalu
whether
variabl
associ
outcom
analysi
found
matern
smoke
first
year
life
relat
pneumonia
outcom
sum
bedroom
allergen
exposur
relat
sinu
infect
howev
logist
model
control
variabl
odd
ratio
chang
less
adjust
therefor
present
unadjust
relationship
statist
test
p
valu
less
consid
statist
signific
statist
procedur
conduct
sa
sa
institut
inc
cari
nc
r
softwar
process
cord
blood
sampl
contain
adequ
number
cell
repres
total
children
enrol
st
loui
site
ureca
cohort
among
newborn
babi
african
american
mean
age
mother
time
deliveri
year
infant
least
parent
asthma
tabl
subject
report
averag
upper
respiratori
tract
infect
cold
wheez
ill
allcaus
hospit
rate
first
year
life
basic
demograph
firstyear
outcom
group
children
significantli
differ
remain
group
children
part
present
analysi
see
tabl
articl
onlin
repositori
wwwjacionlineorg
collect
nasal
lavag
sampl
symptomat
respiratori
episod
n
routin
followup
visit
n
respiratori
tract
virus
detect
symptomat
episod
routin
visit
tabl
ii
human
rhinoviru
found
highest
frequenc
rsv
next
highest
frequenc
subject
symptomat
episod
could
also
detect
asymptomat
subject
togeth
find
indic
major
respiratori
tract
ill
first
year
life
associ
detect
level
respiratori
tract
viral
pathogen
asymptomat
infant
also
high
rate
appar
viral
carriag
distribut
valu
rsvinduc
ifng
mrna
rsv
rna
activ
show
broad
rang
among
subject
popul
suggest
degre
individu
variat
among
subject
respons
tabl
iii
find
suggest
differ
respons
might
translat
variabl
degre
protect
viral
infect
next
investig
whether
individu
variat
antivir
respons
associ
develop
respiratori
tract
fig
correl
ifng
respons
avail
measur
might
associ
subject
atopi
ie
number
parent
asthma
number
parent
hayfev
presenc
parent
asthma
time
initi
screen
relationship
respiratori
tract
infect
select
ifng
respons
found
associ
respons
rsv
titer
activ
frequenc
upper
respiratori
tract
infect
r
p
r
p
r
p
respect
found
associ
ifng
respons
respons
rsv
titer
activ
frequenc
wheez
episod
first
year
life
r
p
r
p
r
p
r
p
respect
also
investig
whether
associ
antivir
respons
occurr
infect
respiratori
nonrespiratori
site
ie
sinu
ear
croup
stomach
well
associ
number
report
hospit
respiratori
tract
ill
found
ifng
respons
rsv
cord
blood
monocyt
cultur
invers
relat
frequenc
ear
infect
p
sinu
infect
p
pneumonia
p
respiratoryrel
hospit
p
fig
found
differ
ifng
respons
croup
stomach
flu
unexplain
fever
fig
data
shown
togeth
find
reinforc
associ
decreas
ifng
respons
rsv
develop
increas
viral
respiratori
tract
infect
first
year
life
studi
provid
evid
decreas
antivir
interferon
respons
time
birth
select
associ
increas
acut
respiratori
tract
infect
first
year
life
among
infant
high
risk
asthma
allerg
diseas
support
relationship
antivir
respons
respiratori
tract
infect
show
rsvdriven
induct
ifng
mrna
product
cord
blood
monocyt
variabl
among
infant
birth
decreas
level
rsvinduc
ifng
mrna
cord
blood
monocyt
associ
signific
increas
frequenc
upper
respiratori
tract
infect
well
preval
ear
infect
sinu
infect
pneumonia
respiratori
tract
ill
requir
hospit
level
rsvinduc
mrna
express
anoth
highli
induc
antivir
system
interferondriven
activ
downstream
target
interferon
receptor
associ
phenotyp
subsequ
ill
symptomat
respiratori
tract
ill
frequent
associ
detect
level
respiratori
viral
pathogen
level
rsvinduc
ifng
mrna
link
type
infect
croup
stomach
flu
caus
type
pathogen
togeth
find
provid
close
relationship
rsvdriven
ifng
mrna
product
develop
viral
respiratori
tract
ill
turn
suggest
possibl
decreas
type
respons
might
lead
increas
type
ill
present
find
offer
distinct
insight
obtain
previous
exampl
other
found
phaand
allergenstimul
ifng
product
cbmc
invers
correl
frequenc
viral
respiratori
tract
infect
first
year
life
howev
studi
like
measur
respons
cell
nonadher
cell
elimin
tcell
mitogen
antigen
use
stimul
moreov
effect
viral
infect
assess
studi
studi
examin
capac
pbmc
produc
ifng
rsvinduc
ill
children
case
cell
activ
phorbol
crosslink
antibodi
tcell
costimulatori
receptor
respons
local
cell
similarli
other
made
attempt
purifi
cell
stimul
cell
tcell
mitogen
separ
quantifi
ifng
mrna
level
approach
taken
previou
report
associ
decreas
ifng
product
cbmc
increas
risk
allerg
sensit
recurr
wheez
might
reflect
focu
tcell
product
ifng
propos
role
h
versu
h
cytokin
develop
atopi
asthma
studi
come
better
recogn
critic
role
innat
immun
system
control
viral
infect
postvir
asthma
particular
interferon
monocytemacrophag
system
requir
protect
immun
respiratori
tract
virus
rsv
system
capabl
drive
postvir
asthma
independ
adapt
immun
system
least
experiment
model
therefor
present
approach
design
directli
assess
innat
immun
respons
viral
infect
done
use
relev
cell
type
purifi
monocyt
stimulu
rsv
infect
well
specif
sensit
method
realtim
quantit
pcr
appli
previous
upshot
first
evid
monocyt
ifng
gene
also
serv
marker
might
even
particip
suscept
infect
infanc
unexpect
find
provid
new
lead
control
antivir
respons
previou
view
ifng
gene
express
silenc
monocyt
lineag
activ
lymphoid
cell
regard
note
ifng
product
gener
attribut
natur
killer
nk
cell
nkt
cell
cell
wherea
monocyt
macrophag
sole
target
ifng
action
inde
studi
atop
diseas
infanc
often
focu
exclus
tcell
product
ifng
circumst
also
like
due
lower
level
ifng
produc
monocyt
macrophag
condit
use
previou
studi
abl
measur
ifng
product
use
sensit
assay
correspond
mrna
whether
level
interferon
product
function
consequ
uncertain
util
biomark
suscept
viral
infect
prove
quit
use
contrast
appear
monocytemacrophag
lineag
critic
host
defens
respiratori
tract
virus
includ
rsv
particular
lung
macrophag
charg
clearanc
infect
cell
without
die
protect
deriv
antiapoptot
surviv
function
chemokin
function
lost
eg
mice
defici
host
suscept
viral
respiratori
tract
infect
work
suggest
also
need
direct
dendrit
cell
traffic
face
viral
infect
observ
consist
link
promot
gene
polymorph
suscept
sever
rsvinduc
bronchiol
nonetheless
find
rsv
induct
gene
express
significantli
associ
viral
respiratori
tract
infect
rate
first
year
life
still
possibl
howev
product
level
lung
macrophag
would
predict
suscept
infect
especi
given
heterogen
monocytemacrophag
popul
circul
lung
studi
conduct
popul
select
high
preval
atop
diseas
howev
expect
ifng
respons
viral
suscept
attribut
atopi
inde
found
associ
ifng
respons
avail
measur
associ
atopi
subject
group
full
evalu
atop
statu
subject
yet
perform
year
age
similarli
other
found
associ
lower
respiratori
tract
ill
first
year
life
occurr
parent
atopi
subject
eczema
find
suggest
viral
suscept
independ
atopi
certainli
evid
case
experiment
model
viral
respiratori
tract
infect
howev
requir
nonatop
cohort
followup
present
cohort
formal
test
relationship
virusinduc
ifng
product
monocyt
viral
suscept
atop
statu
human
subject
molecular
mechan
rsv
induct
ifng
gene
express
still
need
defin
thu
pathogen
recognit
receptor
system
respons
mediat
viral
induct
variou
form
ifna
ifnb
ifnl
rsv
remark
effect
block
induct
signal
interferon
speci
contrast
pathogen
recognit
receptor
system
tolllik
receptor
retino
acid
induc
gene
rigi
like
receptor
rlr
appear
regul
ifng
gene
express
signal
instead
ifng
gene
express
subject
distinct
type
posit
neg
regul
pretranscript
transcript
posttranscript
level
least
case
lymphoid
nk
nkt
cell
howev
regulatori
mechan
studi
monocyt
respons
rsv
cell
type
could
defin
regulatori
mechan
limit
human
sampl
work
open
new
field
research
rsv
common
caus
seriou
respiratori
tract
ill
infanc
sever
rsvinduc
bronchiol
link
subsequ
wheez
illnessasthma
furthermor
paramyxovir
infect
establish
highfidel
experiment
model
asthma
moreov
rsv
relat
paramyxovirus
easili
detect
monocyt
macrophag
lung
henc
chose
rsv
studi
newborn
monocyt
unawar
cours
subsequ
result
would
predict
respiratori
tract
ill
associ
rhinoviru
sever
limit
cell
sampl
size
unabl
test
multipl
virus
analysi
respons
type
virus
includ
rhinoviru
viral
strain
includ
rsv
type
would
valuabl
goal
futur
summari
report
congenit
variat
innat
immun
respons
might
predict
suscept
acut
respiratori
tract
ill
first
year
life
effort
uncov
evid
ifng
mrna
monocyt
respons
viru
rather
tcell
respons
mitogenallergen
might
link
develop
viral
infect
eventu
postvir
asthma
abl
defin
relationship
despit
rel
small
sampl
size
sampl
avail
complex
immunolog
analysi
serv
limit
number
ureca
particip
could
studi
howev
demograph
characterist
cohort
differ
overal
group
suggest
studi
repres
sampl
subject
addit
studi
includ
mostli
african
american
children
therefor
result
might
gener
children
racial
background
interestingli
other
recent
found
interferonstimul
gene
eg
also
link
develop
asthma
particularli
subject
african
descent
find
also
consist
observ
decreas
ifng
product
respons
rsv
pbmc
older
children
adult
allerg
asthma
thu
earli
event
infanc
might
carri
similar
deficit
antivir
defens
later
life
togeth
find
suggest
full
analysi
interferon
product
pathway
might
provid
key
insight
suscept
viral
respiratori
tract
infect
subsequ
chronic
obstruct
lung
diseas
asthma
